VKA + Apixaban + dabigatran + rivaroxaban
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anticoagulation
Conditions
Anticoagulation
Trial Timeline
Jan 1, 2014 → Dec 31, 2019
NCT ID
NCT02640222About VKA + Apixaban + dabigatran + rivaroxaban
VKA + Apixaban + dabigatran + rivaroxaban is a pre-clinical stage product being developed by Bristol Myers Squibb for Anticoagulation. The current trial status is completed. This product is registered under clinical trial identifier NCT02640222. Target conditions include Anticoagulation.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02640222 | Pre-clinical | Completed |
Competing Products
7 competing products in Anticoagulation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban | Pfizer | Approved | 84 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 22 |
| Apixaban + Cofact (4-Factor PCC) + Beriplex P/N (4-Factor PCC) + Placebo (Saline solution) | Bristol Myers Squibb | Phase 1 | 32 |
| four factor prothrombin complex concentrate | CSL | Approved | 84 |
| DOACs: Rivaroxaban, Dabigatran, Apixaban + Standard of care (Warfarin) | Bayer | Pre-clinical | 20 |
| Prismocitrate 18 | Baxter | Phase 3 | 74 |
| Prismocitrate 18 | Baxter | Phase 3 | 74 |